<DOC>
	<DOCNO>NCT01704482</DOCNO>
	<brief_summary>We aim investigate efficacy N-acetylcysteine ( NAC ) attenuate acute renal dysfunction patient rheumatic valvular heart disease undergo single valve replacement .</brief_summary>
	<brief_title>N-acetylcysteine Renal Protection Patients With Rheumatic Heart Disease Undergoing Valve Replacement</brief_title>
	<detailed_description />
	<mesh_term>Heart Diseases</mesh_term>
	<mesh_term>Rheumatic Diseases</mesh_term>
	<mesh_term>Renal Insufficiency</mesh_term>
	<mesh_term>Heart Valve Diseases</mesh_term>
	<mesh_term>Rheumatic Heart Disease</mesh_term>
	<mesh_term>Acetylcysteine</mesh_term>
	<mesh_term>N-monoacetylcystine</mesh_term>
	<criteria>patient rheumatic heart disease undergo single valve replacement End stage renal disease ( plasma creatinine concentration ≥ 300 µmol/L ) Emergency cardiac surgery Planned offpump cardiac surgery Chronic inflammatory disease immunosuppression Chronic moderate high dose corticosteroid therapy ( ≥ 10 mg/day prednisone equivalent ) Age ≤ 18 year .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2012</verification_date>
</DOC>